Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jul 18;12:967493. doi: 10.3389/fcimb.2022.967493

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Chen, Xu, Li, Yi, Jiang, Hao, Xu, Zou, Li, Gao, Tian, Jin, Ren and Li

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Evaluation of the immunogenicity of the VLP. Mice were primed with PBS or SARS-CoV-2 VLPs and boosted three weeks after the prime immunization using the same inocula used for priming. Blood samples were collected from the tail vein of mice at indicated times after the initial vaccination and used to analyze humoral immune responses using an antibody detection kit (The coating antigen used in the kit was RBD protein). Sera collected from the tail vein of pre-immune mice were used as a negative control. *, p< 0.05; **, p< 0.01; ***, p< 0.001; ****, p< 0.0001. The results are expressed as the mean ± standard deviation (SD). (A) Schematic diagram of immunization. (B) changes of total IgG during the immunization. (C) IgG titers at 4, 5, and 6 weeks post initial immunization. (D-F) RBD-specific IgG (D), IgG1 (E), and IgG2a (F) at six weeks post initial immunization. (G) Splenic lymphocyte subtypes.